PPARγ在前列腺癌中的研究进展
Research Progress of PPARγ in Prostate Cancer
DOI: 10.12677/ACM.2023.132272, PDF,   
作者: 常 耀：山东第一医科大学附属省立医院，山东 济南；山东第一医科大学，山东 济南；王子成, 赵德龙, 郭安东, 丁森泰*：山东第一医科大学附属省立医院，山东 济南
关键词: PPARγ；前列腺癌；PPARγ激动剂；PPARγ； Prostate Tumor； PPARγ Agonist
摘要: 过氧化氢酶体增殖物激活受体(peroxisome proliferator-activated receptors, PPARS)是一种核受体超家族中的配体激活转录因子，该受体共有三种亚型，即PPARα、PPARβ/δ、PPARγ。他们在机体内调节脂质激活基因转录、参与脂质代谢、降低炎症反应、细胞增殖和分化。其中PPAR-γ配体具有抗增殖和促分化作用，在前列腺癌中具有抗肿瘤作用。现综述PPARγ在前列腺癌中的研究进展，旨在讨论PPARγ参与前列腺癌发生发展的机制及其在前列腺癌诊断、治疗的潜在价值。
Abstract: Peroxisome proliferator-activated receptors (PPARS) is a ligand-activated transcription factor in the nuclear receptor superfamily, which has three subtypes, namely PPARα, PPARβ/δ and PPARγ. They regulate lipid-activated gene transcription, participate in lipid metabolism, and reduce inflamma-tory response, cell proliferation and differentiation in the body. Among them, the PPAR-γ ligand has anti-proliferation and differentiation-promoting effects, and has anti-tumor effects in prostate can-cer. This article reviews the research progress of PPARγ in prostate cancer, aiming to discuss the mechanism of PPARγ involved in the development of prostate cancer and its potential value in the diagnosis and treatment of prostate cancer.
文章引用：常耀, 王子成, 赵德龙, 郭安东, 丁森泰. PPARγ在前列腺癌中的研究进展[J]. 临床医学进展, 2023, 13(2): 1962-1967. https://doi.org/10.12677/ACM.2023.132272

参考文献

[1] 国家癌症中心, 国家肿瘤质控中心前列腺癌质控专家委员会. 中国前列腺癌规范诊疗质量控制指标(2022版) [J]. 中华肿瘤杂志, 2022, 44(10): 1011-1016.
[2] Siegel, D.A., O’neil, M.E., Richards, T.B., et al. (2020) Prostate Cancer Incidence and Survival, by Stage and Race/ Ethnicity—United States, 2001-2017. MMWR Morbidity and Mortality Weekly Report, 69, 1473-1480. [Google Scholar] [CrossRef] [PubMed]
[3] Rathkopf, D.E., Antonarakis, E.S., Shore, N.D., et al. (2017) Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research: An Official Journal of the American Asso-ciation for Cancer Research, 23, 3544-3551. [Google Scholar] [CrossRef] 
[4] Zhou, Y., Bolton, E.C. and Jones, J.O. (2015) Androgens and Androgen Receptor Signaling in Prostate Tumorigenesis. Journal of Molecular Endocrinology, 54, R15-R29. [Google Scholar] [CrossRef] 
[5] Logothetis, C.J. and Schellhammer, P.F. (2008) High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial. Cancer Prevention Research (Philadelphia, Pa), 1, 151-152. [Google Scholar] [CrossRef] 
[6] Deocampo, N.D., Huang, H. and Tindall, D.J. (2003) The Role of PTEN in the Progression and Survival of Prostate Cancer. Minerva Endocrinologica, 28, 145-153.
[7] Abate-Shen, C., Banach-Petrosky, W.A., Sun, X., et al. (2003) Nkx3.1; Pten Mutant Mice Develop Inva-sive Prostate Adenocarcinoma and Lymph Node Metastases. Cancer Research, 63, 3886-3890.
[8] Ellwood-Yen, K., Graeber, T.G., Wongvipat, J., et al. (2003) Myc-Driven Murine Prostate Cancer Shares Molecular Features with Human Prostate Tumors. Cancer Cell, 4, 223-238. [Google Scholar] [CrossRef] 
[9] Aytes, A., Mitro-fanova, A., Lefebvre, C., et al. (2014) Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF That Drives Prostate Cancer Malignancy. Cancer Cell, 25, 638-651. [Google Scholar] [CrossRef] [PubMed]
[10] Goldstein, A.S., Huang, J., Guo, C., et al. (2010) Identification of a Cell of Origin for Human Prostate Cancer. Science (New York, NY), 329, 568-571. [Google Scholar] [CrossRef] [PubMed]
[11] Dulińska-Litewka, J., Felkle, D., Dykas, K., et al. (2022) The Role of Cyclins in the Development and Progression of Prostate Cancer. Biomedicine & Pharmacotherapy, 155, Article ID: 113742. [Google Scholar] [CrossRef] [PubMed]
[12] Tew, B.Y., Hong, T.B., Otto-Duessel, M., et al. (2017) Vitamin K Epoxide Reductase Regulation of Androgen Receptor Activity. Oncotarget, 8, 13818-13831. [Google Scholar] [CrossRef] [PubMed]
[13] Rosen, E.D. and Spiegelman, B.M. (2001) PPARgamma: A Nu-clear Regulator of Metabolism, Differentiation, and Cell Growth. The Journal of Biological Chemistry, 276, 37731-37734. [Google Scholar] [CrossRef] 
[14] Muntean, C., Sasaran, M.O., Crisan, A., et al. (2022) Effects of PPARG and PPARGC1A Gene Polymorphisms on Obesity Markers. Frontiers in Public Health, 10, Article ID: 962852. [Google Scholar] [CrossRef] [PubMed]
[15] Skóra, B., Matuszewska, P., Masicz, M., et al. (2022) Crosstalk between the Aryl Hydrocarbon Receptor (AhR) and the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Key Factor in the Metabolism of Silver Nanoparticles in Neuroblastoma (SH-SY5Y) Cells in Vitro. Toxi-cology and Applied Pharmacology, 2022, Article ID: 116339. [Google Scholar] [CrossRef] [PubMed]
[16] Hernandez-Quiles, M., Broekema, M.F. and Kalkhoven, E. (2021) PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. Frontiers in Endocri-nology, 12, Article ID: 624112. [Google Scholar] [CrossRef] [PubMed]
[17] Rochel, N., Krucker, C., Coutos-Thévenot, L., et al. (2019) Re-current Activating Mutations of PPARγ Associated with Luminal Bladder Tumors. Nature Communications, 10, 253. [Google Scholar] [CrossRef] [PubMed]
[18] Forootan, F.S., Forootan, S.S., Malki, M.I., et al. (2014) The Expression of C-FABP and PPARγ and Their Prognostic Significance in Prostate Cancer. International Journal of On-cology, 44, 265-275. [Google Scholar] [CrossRef] [PubMed]
[19] Rogenhofer, S., Ellinger, J., Kahl, P., et al. (2012) Enhanced Expression of Peroxisome Proliferate-Activated Receptor Gamma (PPAR-γ) in Advanced Prostate Cancer. An-tiCancer Research, 32, 3479-3483.
[20] Park, H.K., Kim, H., Kim, H.G., et al. (2015) Expression of Peroxisome Pro-liferator Activated Receptor Gamma in Prostatic Adenocarcinoma. Journal of Korean Medical Science, 30, 533-541. [Google Scholar] [CrossRef] [PubMed]
[21] 祝海, 翁博文, 贾勇, 等. Id1介导曲格列酮抑制前列腺癌PC-3细胞侵袭分子机制探讨[C]//中国中西医结合学会泌尿外科专业委员会第十四次全国学术会议暨2016年广东省中西医结合学会泌尿外科专业委员会学术年会. 2016: 773.
[22] Segawa, Y., Yoshimura, R., Hase, T., et al. (2002) Expression of Peroxisome Proliferator-Activated Receptor (PPAR) in Human Prostate Cancer. The Prostate, 51, 108-116. [Google Scholar] [CrossRef] [PubMed]
[23] Dong, F.L., Liu, D.M., Lu, T.T., et al. (2022) PPARγ2 Func-tions as a Tumor Suppressor in a Translational Mouse Model of Human Prostate Cancer. Asian Journal of Andrology, 24, 90-96. [Google Scholar] [CrossRef] [PubMed]
[24] Torrano, V., Valcarcel-Jimenez, L., Cortazar, A.R., et al. (2017) Erratum: The Metabolic Co-Regulator PGC1α Suppresses Prostate Cancer Metastasis. Nature Cell Biology, 19, 873. [Google Scholar] [CrossRef] [PubMed]
[25] Fröhlich, E. and Wahl R. (2015) Chemotherapy and Chemoprevention by Thiazolidinediones. BioMed Research International, 2015, Article ID: 845340. [Google Scholar] [CrossRef] [PubMed]
[26] Yang, C.C., Wang, Y.C., Wei, S., et al. (2007) Peroxisome Prolifera-tor-Activated Receptor Gamma-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation. Cancer Research, 67, 3229-3238. [Google Scholar] [CrossRef] 
[27] Shiau, C.W., Yang, C.C., Kulp, S.K., et al. (2005) Thiazol-idenediones Mediate Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Functions Inde-pendently of PPARgamma. Cancer Research, 65, 1561-1569. [Google Scholar] [CrossRef] 
[28] Qin, L., Gong, C., Chen, A.M., et al. (2014) Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Inhibits Migration and Invasion of Prostate Cancer Cells through Inhibition of the CXCR4/CXCL12 Axis. Molecular Medicine Reports, 10, 695-700. [Google Scholar] [CrossRef] [PubMed]
[29] Qin, L., Ren, Y., Chen, A.M., et al. (2014) Peroxisome Prolifera-tor-Activated Receptor γ Ligands Inhibit VEGF-Mediated Vasculogenic Mimicry of Prostate Cancer through the AKT Signaling Pathway. Molecular Medicine Reports, 10, 276- 282. [Google Scholar] [CrossRef] [PubMed]
[30] Forootan, F.S., Forootan, S.S., Gou, X., et al. (2016) Fatty Acid Ac-tivated PPARγ Promotes Tumorigenicity of Prostate Cancer Cells by Up Regulating VEGF via PPAR Responsive Ele-ments of the Promoter. Oncotarget, 7, 9322-9339. [Google Scholar] [CrossRef] [PubMed]
[31] Ahmad, I., Mui, E., Galbraith, L., et al. (2016) Sleeping Beauty Screen Reveals Pparg Activation in Metastatic Prostate Cancer. Proceedings of the National Academy of Sciences of the United States of America, 113, 8290-8295. [Google Scholar] [CrossRef] [PubMed]
[32] Galbraith, L.C.A., Mui, E., Nixon, C., et al. (2021) PPAR-Gamma Induced AKT3 Expression Increases Levels of Mitochondrial Biogenesis Driving Prostate Cancer. Oncogene, 40, 2355-2366. [Google Scholar] [CrossRef] [PubMed]
[33] 温珊, 苏衍萍. PPARγ的抗肿瘤作用的研究进展[J]. 世界最新医学信息文摘, 2019, 19(63): 100-101.
[34] 朱绍兴, 陈流, 王彬. 吡格列酮诱导前列腺癌PC-3细胞凋亡的实验研究[J]. 福建医科大学学报, 2008(5): 404-407.
[35] Chang, S.N., Lee, J.M., Oh, H., et al. (2018) Troglitazone Inhib-its the Migration and Invasion of PC-3 Human Prostate Cancer Cells by Upregulating E-Cadherin and Glutathione Pe-roxidase 3. Oncology Letters, 16, 5482-5488. [Google Scholar] [CrossRef] [PubMed]
[36] Yoshimura, R., Matsuyama, M., Hase, T., et al. (2003) The Effect of Peroxisome Proliferator-Activated Receptor- Gamma Ligand on Urological Cancer Cells. International Journal of Mo-lecular Medicine, 12, 861-865. [Google Scholar] [CrossRef] 
[37] Chaffer, C.L., Thomas, D.M., Thompson, E.W., et al. (2006) PPAR-gamma-Independent Induction of Growth Arrest and Apoptosis in Prostate and Bladder Carcinoma. BMC Cancer, 6, 53. [Google Scholar] [CrossRef] [PubMed]
[38] Suzuki, S., Mori, Y., Nagano, A., et al. (2016) Pioglitazone, a Perox-isome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. International Journal of Mo-lecular Sciences, 17, 2071. [Google Scholar] [CrossRef] [PubMed]
[39] Uemura, H., Hoshino, K. and Kubota, Y. (2011) Role of Ren-in-Angiotensin System and Antitumor Effect of ARB in Prostate Cancer. Nihon Rinsho Japanese Journal of Clinical Medicine, 69, 155-159.
[40] Woo, Y. and Jung, Y.J. (2017) Angiotensin II Receptor Blockers Induce Autophagy in Prostate Cancer Cells. Oncology Letters, 13, 3579-3585. [Google Scholar] [CrossRef] [PubMed]

为你推荐